Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-04-04
2008-10-14
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S184100, C424S185100, C424S116000, C424S094100, C424S130100, C514S019300, C514S002600, C435S183000, C435S212000, C435S195000, C435S113000
Reexamination Certificate
active
07435420
ABSTRACT:
The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain.Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV—like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.
REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne et al.
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4024250 (1977-05-01), Palm
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6319893 (2001-11-01), Demuth et al.
patent: 7132104 (2006-11-01), von Horsten et al.
patent: 25 42 598 (1976-04-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-10-01), None
patent: 0 995 440 (2000-04-01), None
patent: 2.085.665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 04-334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/62266 (2001-08-01), None
Amasheh, et al.; “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus laevis oocytes”;Journal of Physiology; (1997); 504(1): 169-174.
Arai, et al. “Synthesis of Prolyl Endopeptidase Inhibitors and Evaluation of Their Structure-Activity Relationships: In Vitro Inhibition of Prolyl Endopeptidase from Canine Brain”;Chem. Pharm. Bull.; (1993); 41(i): 1583-1588.
Ashworth, et al.; “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”;Bioorganic&Medicinol Chemistry Letters; (1996); 6(10): 1163-1166.
Badia-Elder, et al; “Effects of Neuropeptide (NPY) on Ethanol Intake and Anxiety in High and Low Alcohol Drinking (Hadi/Ladi) rats”;Purdue School of Science; (2000).
Campbell, et al.; “Sulphonylureas and metformin: efficacy and inadequacy”;New Antidiabetic Drugs; (1990); 33-51.
Ekkehard, et al.; Chemical Abstracts; (1991); vol. 115, p. 14, Abstrct No. 149947q.
Hosoda, et al.; Chemical Abstracts; (1993) vol. 118, p. 21, Abstract No. 255342k.
Deacon, et al.; “Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I are Rapidly Degraded from the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects”;Diabetes; (1995); 4: 1126-1131.
Duncan; “Diseases of Metabolism: Detailed Methods of Diagnosis and Treatment”; (1964); 951-957.
Durinx, et al.; “Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters”;Clin. Chem. Lab. Med.; (2001); 39(2): 155-159.
Edwards, et al.; “Synthesis and activity of NH2- and COOH-terminal elastase recognition sequences on cotton”;J. Peptide Res.; (1999); 54: 536-543.
Endroczi, et al.; “Dipeptidyl Peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn2+In Vitro”;Acta Physiologica Hungarian(1996); 75(1): 35-44.
Frohman, et al.; “Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma In Vitro and In Vivo to a biologically Inactive Product Cleaved at the NH2Terminus”;J. Clin. Invest.; (1986); 78: 906-913.
Goodman & Gilman's; “Hormone and Hormone Antagonists”;The Pharmacological Basis of Therapeutics Ninth Edition; (1996); 1510.
Gossrau; “Cytochemistry of membrane proteases”;Histochem J.; (1985) 17(7): 737-71.
Gutniak, et al.; “Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”;New England J. Med.; (1992); 326: 1316-1322.
Hahn, et al.; “Enzyme histochemical evidence for the presence of potential blood pressure regulating proteases in cultured villous explants from human first trimester placentae”;Acta Histochem; (1993); 95(2): 185-92.
Heymann & Mentlein; “Has dipeptidyl peptidase IV an effect on blood pressure and coagulation”;Klin Wochenschr; (1984); 62(1): 2-10.
Lee & Lee; “Cathepsin B inhibitory peptides derived from •-casein”;Peptides; (2000); 21: 807-809.
Kieffer, et al.; “Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV”;Endocrinology; (1995); 136: 3585-3596.
Korom, et al.; “Inhibition of CD26/Dipeptidyl Peptidase IV Activity in Vivo Prolongs Cardiac Allograft Survival in Rat Recipients”;Transplantation; (1997); 54(10): 1495-1500.
Lader; “Assessment Methods and the Differential Diagnosis of Anxiety”;Journal of Clinical Psychopharmacology; (1981); 1(6): 342-349.
Lin, et al.; “Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics”;Proc. Nat. Acad. Sci. USA; (1998); 95: 14020-1402.4.
Magyar, et al.; “Proximal rubule Na transporter responses are the same during acute and chronic hypertension”;Am. J. Physiol. Renal. Physiol.; (2000); 279(2) F358-369.
Mannucci, et al.; “Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects”;Diabetes Care; (2001); 24(3): 489-494.
Martindale: The Extra Pharmacopoeia—Thirtieth Edition (1993) p. 1619.
Martindale: The Extra Pharmacopoeia—Thirtieth Edition (1993) p. 36.
Mentlein, et al.; “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”;Regulatory Peptides; (1993); 49: 133-144.
Munglani, et al.; “The Therapeutic Potential of Neuropeptide Y”;Review Article Cambridge University; (1996); 371-389.
Nathan, et al.; “Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects”;Diabetes Care; (1991); 15(2): 270-276.
Papies, et al.; “Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension”;Cor Vasa; (1991); 33(3): 218-26.
Pauly, et al.; Abstracts Issue: Abstracts from the 11thInternational Symposium on Regulatory Peptides;Regulatory Peptides; (1996); 64(103): 148.
Demuth, et al.; Pschyrembel Klinisches Worterbuch (1994) (9 pages).
Qureshi, et al.; “Endogenous neuropeptide Y mediates vasoconstriction during endotoxic
Demuth Hans-Ulrich
Hoffmann Matthias
Kask Ants
Kruber Susanne
Nguyen Huu Phuc
Chernyshev Olga N
Probiodrug (AG)
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Dipeptidyl peptidase IV inhibitors for the treatment of anxiety does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipeptidyl peptidase IV inhibitors for the treatment of anxiety, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptidyl peptidase IV inhibitors for the treatment of anxiety will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4003764